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Introduction
Photodynamic therapy (PDT) is now an established clini-
cal cancer treatment.1 PDT utilizes the combination of a
photosensitizing compound, light and oxygen to generate
reactive oxygen species (ROS) in situ, thus promoting
destruction of localized neoplastic lesions.2,3 As a conse-
quence of the short lifetime of ROS, the oxidative damage
is limited to a spherical area of no more than 10 nm sur-
rounding the photosensitizer that generated it; this small
area, combined with the ability to direct light with high
precision via fibre optics, gives PDT a high degree of spa-
tial control. PDT is employed in most of the developed
countries of the world with good effect; however, the
selectivity of commercial PDT agents, such as Photofrin
(Axcan Pharma Inc., Quebec, Canada), Foscan (Biolitec
Pharma Ltd, Dublin, Ireland) and Verteporfin (QLT
Inc., Vancouver, Canada), for tumour tissue remains an
area where there is considerable room for improvement.
Typically, tumour to peritumoural tissue ratios are signi-
ficantly below 10 : 1 at the time of treatment.4 Lack of
selectivity requires the administration of higher doses of
photosensitizer to achieve the desired clinical effect, which
can lead to generalized photosensitivity for the patient
and a reduced safety margin when treating tumours in
sensitive areas, such as the brain.
It is unsurprising that relatively low tumour to peri-
tumoural tissue ratios are achieved, as a result of the fact
that the photosensitizer is usually not targeted in any spe-
cific manner. In the case of cancer, accumulation at the
desired site simply relies on the poorly developed and
permeable neovasculature together with a lack of suffi-
cient lymphatic drainage,5 leading to the enhanced pene-
tration and retention effect. Recently, there has been great
interest in targeting photodynamic sensitizers more accu-
rately, using a variety of strategies.6 One way in which
accurate delivery of photosensitizers can be achieved is by
conjugation to antibodies that recognize tumour-associ-
ated antigens.7 Such compounds allow the direct targeting
of the photosensitizer to the correct cell type, as well as
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Summary
Two cationic porphyrins bearing an isothiocyanate group for conjugation
to monocolonal antibodies have been synthesized. The two porphyrins
conjugated efficiently to three monoclonal antibodies (anti-CD104, anti-
CD146 and anti-CD326), which recognize antigens commonly over-
expressed on a range of tumour cells. In vitro, all conjugates retained the
phototoxicity of the porphyrin and the immunoreactivity of the antibody.
Mechanistic studies showed that conjugates formed from the mono- and
tri-cationic porphyrin and anti-CD104 antibody mediated apoptosis fol-
lowing irradiation with non-thermal red light of 630 ± 15 nm wavelength.
In vivo antibody conjugates caused suppression of human LoVo tumour
growth in immunodeficient NIH III mice, similar to the commercial pho-
todynamic therapy (PDT) agent Photofrin, but at administered photo-
sensitizer doses that were more than two orders of magnitude lower.
Positron emission tomography (PET) following PDT showed a large, early
increase in uptake of 18fluorodeoxyglucose (FDG) by tumours treated
with the anti-CD104 conjugates. This effect was not observed with Photo-
frin or with conjugates formed from the same photosensitizers conju-
gated to an irrelevant antibody.
Keywords: bioconjugation; head and neck cancer; monoclonal antibody;
photodynamic therapy
256  2010 The Authors. Immunology  2010 Blackwell Publishing Ltd, Immunology, 132, 256–265
IMMUNOLOGY OR IG INAL ART ICLE
quicker clearance of the conjugate from the blood stream,
resulting in a reduced risk of photosensitisation to normal
tissues. The easiest way to achieve a stable and active anti-
body conjugate is to link the photosensitizers covalently
to the antibody in a defined manner.8
Over the past decade we have developed a highly effi-
cient method for conjugating photodynamic sensitizers to
proteins based on mono-isothiocyanato (NCS) porphy-
rins.9–12 Advantages of this method, compared with other
methods of conjugation, such as carbodiimide mediated
coupling of carboxy-bearing photosensitizers and the use
of activated esters, include the following.
(1) No opportunity for protein cross-linking exists, as
only one amine-reactive NCS group is presented on
each photosensitizer molecule. This contrasts with
naturally occurring porphyrins such as haem-
atoporphyrin (Hp), and chlorin e6, which bear multi-
ple carboxyl groups.
(2) The NCS group, unlike the carboxyl groups of Hp
and chlorin e6, which require activating agents, reacts
spontaneously with amino groups of lysine residues
by an addition rather than substitution reaction. This
bypasses the need to separate the conjugate from by-
products generated by the activating agent.
(3) Generic synthetic routes to NCS porphyrins allow
control of factors such as solubility and charge, by
incorporation of suitable groups early in the synthe-
sis. Such factors allow minimization of non-covalent
binding of photosensitizer to the protein, as well as
the potential targeting of photosensitizer to specific
intracellular sites following internalization.
A large number of variations of this general class of
compounds using different NCS porphyrin/antibody
combinations have been screened, and now a set of con-
jugates which are highly selective for antigens over-
expressed on a range of tumours, including colorectal
and lung, are reported. The antigens chosen were
CD104 (b4 integrin), CD146 (melanoma cell adhesion
molecule) and CD326 (epithelial cell adhesion molecule).
Previous studies on conjugates of porphyrins with inter-
nalizing versus non-internalizing antibodies have shown
the internalizing conjugates to be more powerful PDT
agents,11 so for this reason antibodies have been selected
that correspond to antigens that are known to internal-
ize following ligand binding. Two well-established
human cell lines originating from colorectal and lung
tumours (LoVo and CORL23, respectively), which show
differential expression of these cell antigens, were used
to demonstrate proof of concept. Lung tumours are rou-
tinely treated with PDT and there are ongoing clinical
trials investigating efficacy in colorectal malignancies.1
Specific immunoconjugates show enhanced photody-
namic activity in vitro, against LoVo and CORL23 cells,
and suppress the growth of tumours that over-express
antigens corresponding to the relevant conjugates
in vivo.
Materials and methods
Synthetic procedures
Synthesis of isothiocyanato porphyrins was achieved using
procedures similar to those previously reported.10
Cell lines and antibodies
The LoVo human colon adenocarcinoma and CORL23
human large cell lung carcinoma (ECACC) cell lines were
grown in Dulbecco’s modified Eagle’s minimal essential
medium (DMEM) and RPMI, respectively. All medium
was supplemented with 10% [volume/volume (v/v)] fetal
calf serum, 2 mM L-glutamine, 100 lg/ml streptomycin
and 100 lg/ml penicillin (Invitrogen, Paisley, UK). Cells
were maintained at 37 in a humidified incubator with a
5% CO2 atmosphere.
The mouse anti-human antibodies, anti-CD104, anti-
CD146 and anti-CD326, were all purchased from AbD
Serotec (Kidlington, Oxford, UK). Anti-CD104 binds to a
205-kDa glycoprotein involved in cell–cell adhesion that
is up-regulated in colorectal and bladder carcinomas.
Anti-CD146 (Muc-18) binds a 113-kDa glycoprotein that
has been reported to be expressed on metastatic tumours.
Anti-CD326 (EpCAM) recognizes a 40 kDa cell–cell adhe-
sion molecule up-regulated on many carcinomas, particu-
larly colorectal.
Conjugation to monoclonal antibodies
Conjugation was carried out as described previously.11
Briefly, the antibody and porphyrin 1 or 2 (Fig. 1) were
agitated gently at room temperature for 1 hr, while being
protected from light. Conjugates were purified using
Sephadex G25 columns (Amersham, Buckinghamshire,
UK) and eluted with phosphate-buffered saline (PBS), pH
74. The degree of labelling (the number of moles of por-
phyrin conjugated per mole of antibody) was calculated
using spectroscopic methods.12 Immunoconjugates were
centrifuged at 13 000 g for 10 min to remove any traces
of aggregates, and then the supernatant was filtered
through a 02-lm syringe filter prior to storage at 4 or,
for long-term storage, at )20.
Flow cytometry
Cells were removed from culture vessels with 5 mM ethy-
lenediaminetetraacetic acid (EDTA) in PBS. After washing
in PBS, cells were counted and re-suspended in PBS/
025% w/v bovine serum albumin (BSA) and 2 · 105 cells
were added to each Falcon 2054 fluorescence-activated
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cell sorter (FACS) tube (BD Biosciences, Oxford, UK). The
cells were labelled with 50 ll (5 lg/ml) of the test anti-
body, either conjugated or unconjugated, for 1 hr at 4.
After washing with PBS/BSA, cells were labelled with 5 ll
(10 lg/ml) of rabbit anti-mouse immunoglobulin G
(IgG)-fluorescein isothiocyanate (FITC) (AbD Serotec) for
1 hr at 4. A further wash with PBS/BSA was performed
before analysis of cells in a FACS Calibur flow cytometer
running CELLQUEST PRO v3.3 (BD Biosciences, Oxford, UK).
In vitro cytotoxicity
Cells were removed from culture vessels with 5 mM EDTA
in PBS, washed and counted, and 1 · 105 cells were
added to 5-ml polypropylene tubes. Antibody immuno-
conjugates and unconjugated porphyrin were diluted in
serum-free medium, added to the cells, and incubated at
37 for 6 hr. Cells were washed three times with medium
to remove unbound immunoconjugate or porphyrin,
re-suspended in complete medium and plated out in
duplicate in two 96-well plates (25 · 104 cells/well). One
plate acted as the dark control (i.e. no irradiation) while
the other was irradiated with 15 J/cm2 of cooled and fil-
tered red light (630 nm) delivered by a Paterson light sys-
tem (Paterson Lamp BL1000A, bandpass 630 ± 15 nm
filter; Phototherapeutics Ltd; Altricham, UK). The plates
were incubated at 37 overnight before a commercial
MTS assay (Promega, Southampton, UK) was performed.
The percentage of cell survival was calculated in propor-
tion to the number of cells incubated without photosensi-
tizer. All assays were performed in quadruplicate.
Assessment of mitochondrial membrane potential
with JC-1
The MitoProbe JC-1 assay kit (Molecular Probes, Invitro-
gen, Paisley, UK) was used according to the manufac-
turer’s instructions. Briefly, LoVo or CORL23 cells
(1 · 106/ml) were re-suspended in PBS to which freshly
reconstituted JC-1 dye solution was added to give a final
concentration of 2 lM. Cells were incubated for 15 min,
washed to remove excess dye and analysed by flow
cytometry. JC-1 is taken up by cells and will accumulate
in the mitochondria of healthy, functioning cells where it
fluoresces (peak emission 590 nm) in the FL-2 channel of
a flow cytometer; however, if the mitochondrial mem-
brane potential is disrupted, JC-1 ‘leaks’ into the cyto-
plasm and breaks down into the monomeric form that
fluoresces (peak emission 529 nm) in the FL-1 channel.
Assessment of apoptosis
The proportion of cells undergoing apoptosis (annexin
positive) or necrosis (annexin and propidium iodide dual
positive) was determined using a standard flow cytometry
Annexin-V-FITC binding assay according to the manufac-
turer’s instructions (AbD Serotec).
Caspase 3 activation was measured using a polyclonal
rabbit anti-human caspase 3 antibody (1 : 1000 dilution,
AHP476; AbD Serotec) that binds both the 32-kDa pro-
caspase and the active (17-kDa) moiety, detected with a
horseradish peroxidase (HRP)-conjugated sheep anti-rab-
bit secondary antibody and ECL Western Blotting Detec-
tion Reagents (Amersham). Cell death was assessed by
both methods following incubation with immunoconju-
gates and red-light illumination.
In vivo tumour response
Immunodeficient NIH III mice bearing two LoVo
tumours (diameter 5–6 mm; one in each leg) were
injected with Photofrin (5 mg/kg or 83 lmol/kg using
the molecular weight for monomeric hematoporphyrin;
Photofrin is a mixture of haematorporphyrin oligomers)
or conjugate (10 nmol/kg) 24 hr prior to irradiation: one
tumour per mouse was irradiated while the second served
as an unirradiated control. The light source was a
1000 W mercury-xenon lamp with two glass filters (Cori-
on LL590 and LS700; Newport Corporation, Stratford,
CT) to give light between 590 and 650 nm. The light was
fed into a fibre-optic cable to permit irradiation in a lam-
inar flow hood. The fluence at the delivery end of the
cable was 26 mW. The total dose given to each tumour
was 200 J/cm2. Tumour volume was calculated by mea-
suring the diameter of the tumours with a calliper.13,14
PET investigation of PDT tumour response
Mice were imaged 24 hr, 48 hr or 1 week after PDT.
Images were acquired using the LabPet Small Animal
scanner (University of Sherbrooke, Sherbrooke, QC,
Canada), with a resolution of 135 mm full width at
half-maximum peak height transaxial.15 The animal was
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Figure 1. Structures of 5-(4-isothiocyanatophenyl)-15-(4-(3-N-methyl-
pyridiniumyl)phenyl) porphyrin (porphyrin 1) and 5-(4-isothiocyanato-
phenyl)-10,15,20-tri(4-(3-N-methylpyridiniumyl)phenyl) porphyrin
(porphyrin 2).
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anaesthetized under isoflurane anesthesia (1% at 2 l/min
oxygen flow) and 37 MBq of 18F fluorodeoxyglucose
(FDG) was administrated via the caudal vein in 200–
300 ll of physiological saline. To obtain a more accurate
measure of the injected FDG dose, the radioactivity in
each animal was quantified in the well radioactivity coun-
ter immediately after injection of the radiotracer. The
mouse was then revived and replaced in its cage until the
scan. This procedure reduced the time spent by the ani-
mal under anaesthesia. Imaging was initiated 60 min after
intravenous administration and lasted for 20 min. The
animal was anaesthetized immediately before imaging and
was placed supine on the bed of the camera and kept
warm with a warm air flow system. A single bed position
was used with both the radial and axial double sampling
modes. The images were reconstructed using 10, 15 and
20 iterations of the maximum likelihood expectation
maximization (ML-EM) algorithm that models detector
response.16 Overall, 31 images in 128 · 128 pixel format
(voxel size of 05 · 05 · 1193 mm3) were obtained, cov-
ering 37 mm axially. Images were then used to quantify
FDG uptake in the regions of interest (treated and
untreated tumours). After imaging, the mice were sacri-
ficed.
Images were analysed with the SHERBROOKE LAB-TEP soft-
ware (University of Sherbrooke, QC, Canada). To quan-
tify tumour 18FDG uptake we first selected all the slides
on which the tumours were visible. We drew a region of
interest (ROI) surrounding the tumour on each of these
slices, revealing the partial activity. The activities of each
ROI were then summed to obtain the total radioactivity
content of the tumour. The results were then expressed as
the %ID/mm3 of tumour by taking into account the cor-
rection for 18FDG decay and the counting efficiency of
the scanner.
Results
Photosensitizer synthesis
Previous studies of porphyrin-based isothiocyanato por-
phyrins have demonstrated that the combination of cat-
ionic charge with a single isothiocyanate group is optimal
for bioconjugation.10,17 Amphiphilicity has also been
shown to be important for good PDT activity.4 We have
identified two structures that combine these physico-
chemical characteristics (Fig. 1).
Antibody labelling with porphyrin photosensitizers
A series of in vitro experiments were initially undertaken
to verify the integrity of a series of immunoconjugates
utilizing different antibodies. Firstly, the degree of por-
phyrin labelling was assessed spectroscopically and, after
optimization of the conjugation procedure, an average of
11 photosensitizer per antibody was achieved, which was
slightly lower than previous results using 35A7, FSP77
and 171A antibodies (average of 18).11
Having demonstrated that several different antibodies
could successfully be conjugated to both porphyrin deriv-
atives, flow cytometry was used to assess whether this
process affected antibody binding. Figure 2 clearly dem-
onstrates that conjugation did not significantly affect anti-
body reactivity, neither reducing binding as a result of
steric hindrance caused by conjugation to amino acid res-
idues in, or close to, the complementarity-determining
regions, nor increasing non-specific interactions resulting
from changes in hydrophobicity. As expected, all three
antibodies bound to CORL23 and only anti-CD104 and
anti-CD326 bound to the LoVo cells, reflecting the
absence of CD146 on LoVo cells.
Photocytotoxicity in vitro
Phototoxicity of conjugates and a non-conjugated ‘con-
trol’ porphyrin was assessed as previously reported.17
Because of the reactive nature of the isothiocyanate group
the ‘control’ porphyrins were prepared by reacting
porphyrin 1 and porphyrin 2 (Fig. 1) with an excess of
propylamine. The resulting product represented the
photosensitizer with an identical thiourea linkage to the
conjugates, but with a short propyl chain in place of
the antibody. Table 1 shows the LD50 values (dose of
porphyrin needed to kill 50% cells) for the six immuno-
conjugates, compared with the corresponding porphyrin
‘control’. Although it was clear that the immunoconju-
gates had approximately 10-fold lower LD50 compared
with their respective ‘control’ porphyrins, a non-specific
PDT effect was observed. This was shown by the relatively
similar LD50 for the anti-CD146 conjugates against LoVo;
a cell line that does not express the CD146 antigen.
The in vitro data shown in Table 1 were obtained with
a 6-hr incubation period, in order to allow time for inter-
nalization of antigens and any bound antibody. It was
thought likely that the extended length of time (for simi-
lar experiments using no conjugated photosensitizers a
1-hr incubation is normal) permitted the non-specific
enhancement of phototoxicity seen with the anti-CD146/
LoVo combination. It should be noted, however, that
with both photosensitizers the minimum enhancement of
photocytotoxicity, as compared with porphyrin alone, was
obtained with the anti-CD146 conjugates.
Anti-CD104-porphyrin mode of cell death
The mechanism of cell death is highly relevant to the
treatment of some cancers, as the promotion of apoptotic,
rather than necrotic, mechanisms can reduce scarring and
lead to regeneration of functional tissue. An early stage of
apoptosis is the ‘flipping’ of phosphatidyl serine (PS)
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from the inner to the outer side of the plasma membrane,
which is detectable with Annexin V-FITC. To investigate
the possible mechanisms of cell death, cells were incu-
bated with anti-CD104-porphyrin 1 immunoconjugates
for 6 hr before irradiation with 15 J/cm2 light. Cell death
was then assessed for Annexin-V/propidium iodide bind-
ing 15 min post-irradiation (Fig. 3). At the LD25 concen-
tration the cells behaved similarly; however, from LD50
and above the LoVo cells were more sensitive to the
effects of PDT, with a greater percentage in the upper
right (apoptotic and necrotic) quadrant. At LD75 LoVo
cells appeared markedly more sensitive to killing, with the
vast majority of cells in the upper right quadrant com-
pared with 45% of CORL23. The latter cell type also
showed 30% in the lower right (apoptotic) quadrant at
the highest drug dose, whereas the LoVo cells had ‘pro-
gressed’ to necrosis. A similar trend was seen with the
other immunoconjugates, with LoVo showing higher lev-
els of necrotic cell death; surprisingly, the anti-CD146
conjugate also showed high levels of non-specific toxicity
(data not shown).
It has also been shown previously that photosensitiz-
ers that localize to the mitochondria are very rapid
inducers of apoptosis, as compared with those that
localize in the lysosomes or the plasma membrane.18
After irradiation, mitochondrially localized photosensitiz-
ers cause immediate release of cytochrome C and associ-
ated disruption of the mitochondrial membrane
Table 1. Immunoconjugate LD50 concentrations from in vitro cyto-
toxicity assay
LoVo (lm) CORL23 (lm)
Porphyrin 1 2 3
Anti-CD326-porphyrin 1 057 04
Anti-CD146-porphyrin 1 105 072
Anti-CD104-porphyrin 1 068 068
Porphyrin 2 6 35
Anti-CD326-porphyrin 2 043 04
Anti-CD146-porphyrin 2 076 05
Anti-CD104-porphyrin 2 048 025
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Figure 2. Conjugated and unconjugated anti-CD326, anti-CD146 and anti-CD104 were analysed by flow cytometry for binding to CORL23 and
LoVo cells [black line, negative control; blue line, unconjugated antibody; red line, immunoconjugates with porphyrin 1 (a) or porphyrin 2 (b)].
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potential. These events are quickly followed by activation
of various caspases, particularly caspase-3. Here we have
shown that the mitochondrial membrane potential, as
measured by JC-1 dye staining, is significantly disrupted
by both porphyrin derivatives, with the effect being
most pronounced for the anti-CD104-porphyrin 1
reagent (Fig. 4). Once again, LoVo cells appeared to be
far more susceptible to photodynamic-induced damage,
as shown by the almost complete destruction of the
cells, when assayed by flow cytometry. Such a clear dif-
ference in susceptibility was not observed in the MTS
assay (Table 1), probably as a result of the fact that the
latter assay is assessing a more general measure of cell
metabolism, rather than the specific function of the
mitochondria.
Furthermore, when the cells were assayed for procas-
pase 3 conversion to active caspase 3, with associated
commitment to apoptotic cell death, it was clear that,
although this occurred in both cell types, once again it
was considerably faster in LoVo cells. Figure 5 shows pro-
caspase 3 activation in LoVo and CORL23 cells following
incubation with an LD75 concentration of anti-CD104-
porphyrin 1 for 6 hr and irradiation with 15 J/cm2 light.
Cell lysates were prepared immediately (0 min) and at
15 min, 15 hr and 3 hr post-irradiation and were
analysed by western blotting. Loss of procaspase 3
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Figure 3. CORL23 and LoVo cells were treated with LD25, LD50 and LD75 concentrations of anti-CD104-porphyrin 1 and incubated for 6 hr
prior to irradiation at 15 J/cm2. Cells in the lower left quadrant are viable, those in the lower right quadrant are apoptotic and those in the upper
right quadrant are necrotic; 10 000 events were analysed for each sample.
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demonstrates activation, which was completed ‘immedi-
ately’ following irradiation in LoVo cells, whereas more
than 15 hr was required to obtain a similar effect with
the same immunoconjugate against CORL23.
In vivo PDT studies in a LoVo xenograft tumour
model
The above in vitro investigations suggested that photosen-
sitizer–antibody conjugates could be prepared which
maintained both the immunoreactivity of the antibody
and the phototoxicity of the photosensitizer. Mechanistic
studies also suggested a significant apoptotic contribution
to photodynamic cell death. The major goal of any anti-
body–toxin conjugate is, however, the successful delivery
of the cytotoxin efficiently to the target tissue, with a sub-
sequent enhanced therapeutic effect. In order to demon-
strate this for the conjugates described here, an in vivo
model system was designed which allowed tumours of
one of the cell types used for our in vitro studies to be
grown into solid tumour masses on NIH III immunodefi-
cient mice. In order to allow direct ‘benchmarking’
against a commercially available clinical PDT agent,
Photofrin was included in these studies.
Photodynamic treatment was conducted by intrave-
nous injection of immunoconjugates, or Photofrin, into
mice bearing two tumours, one on each hind leg. One
tumour was then irradiated, while the second was pro-
tected from light and acted as a control. Doses of
immunoconjugates (10 nmol/kg) were based on injected
photosensitizer concentrations, which were determined
spectroscopically. Photofrin was administered at a stan-
dard dose (5 mg/kg; equivalent to 83 lmol/kg) used for
PDT treatment of tumour-bearing mice. Two relevant
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Figure 4. Cells were incubated with LD75 concentrations of anti-CD104-porphyrin 1 for 6 hr prior to irradiation at 15 J/cm
2. Cells were then
labelled with 2 lm JC-1 dye for 15 min and then analysed by flow cytometry; 10 000 events were analysed for each sample. At least 90% of cells
showed a decrease in red fluorescence, indicating a disruption of mitochondrial membrane potential.
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Figure 5. Cells (1 · 105) were lysed in reducing sample buffer, over
a range of times, following 6 hr of incubation with anti-CD104-por-
phyrin 1 and then irradiation at 15 J/cm2. Following sodium dodecyl
sulphate–polyacrylamide gel electrophoresis (SDS-PAGE) and wes-
tern blotting with an anti-caspase 3 polyclonal rabbit anti-human
immunoglobulin G (IgG) (1 : 1000) antibody, loss of the 32-kDa
procaspase 3 was observed; however, the 17-kDa active form was not
detectable. Caspase 3 activation was far more rapid in LoVo than the
CORL23 cells.
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(anti-CD104-porphyrin 1 and anti-CD104-porphyrin-2)
conjugates and two irrelevant (anti-CD146-porphyrin 1
and anti-CD146-porphyrin 2) conjugates (to act as con-
trols) were investigated, and compared with Photofrin.
Figure 6 shows the growth of PDT-treated tumours
for anti-CD104-porphyrin 1, anti-CD104-porphyrin 2,
anti-CD146-porphyrin 1, anti-CD146-porphyrin 2, and
Photofrin, relative to non-irradiated control tumours
on the same animal.
Clearly, PDT using both relevant conjugates and Photo-
frin inhibited tumour growth at shorter time-points
post-irradiation; however, by day 12 the Photofrin-trea-
ted tumour matched the control, while for both anti-
CD104 conjugates treated tumours were still significantly
smaller relative to untreated controls. The irrelevant anti-
body (anti-CD146) conjugates gave no significant growth
inhibition at any time-point, demonstrating that the effect
seen with relevant conjugates is attributable to the bind-
ing of anti-CD104 with antigens on the LoVo tumours.
The tumour inhibitory effects of conjugates are remark-
able when it is considered that the effective administered
dose of porphyrin 1 and porphyrin 2 bound to anti-
CD104 is between 2 and 3 orders of magnitude less than
the dose of Photofrin used. Comparing these results
with those for Photofrin and the irrelevant conjugates
(anti-CD146-porphyrin 1 and 2), it can be seen that the
longer term growth inhibition (day 12) was not found
when treating with a clinically relevant PDT drug, nor
when porphyrin 1 or porphyrin 2 was bound to an anti-
body that cannot react with its complementary cell sur-
face antigen. We believe that this demonstrates that the
enhancement of photodynamic activity is directly linked
to the ability of the anti-CD104 antibody to deliver
photosensitizers efficiently to the target tissue.
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Figure 6. Immunodeficient NIH III mice bearing two LoVo tumours (diameter 2–3 mm; one in each leg) were injected with Photofrin (5 mg/
kg) or conjugate (10 nmol/kg) 24 hr prior to irradiation: one tumour per mouse was irradiated while the second served as an unirradiated con-
trol. Tumour size was measured by calliper and growth was followed to 12 days post-irradiation. Tumour size for three mice per point was aver-
aged and the standard error is shown.
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Finally, in order to gain a preliminary insight into pos-
sible mechanisms of tumour growth inhibition resulting
from photodynamic treatment, PET was used to follow
the energetic state of the tumour mass. In order to
achieve this, PDT procedures were repeated as for the
tumour growth inhibition experiments described above,
but at time-points (1, 2 and 8 days) post PDT, animals
were infused with FDG. PET images of the animals were
then acquired and the uptake of FDG in the tumour vol-
ume quantified. As is clearly shown in Fig. 7 the anti-
CD104-porphyrin immunoconjugates gave markedly
increased levels of FDG uptake, especially at day 1 post-
irradiation, compared with the irrelevant (anti-CD146)
reagents or Photofrin. No significant differences were
observed between the red-light treated and untreated
tumours with either irrelevant immunoconjugate or
Photofrin.
Discussion
The results presented here clearly demonstrate that target-
ing of photodynamic sensitizers, by conjugation to mono-
clonal antibodies, can result in significant tumour
response in vivo (Fig. 6). This is similar to the results
obtained for the clinically relevant photosensitizer Photo-
frin at shorter time periods post-therapy, but by day 12
only the anti-CD104 conjugates gave a significant differ-
ence between treated and untreated tumour volumes. The
fact that these enhanced photodynamic results were
obtained at an administered dose more than two orders
of magnitude less than that for Photofrin makes this
even more remarkable. The ability to retard tumour
growth to the same extent as, or to a greater extent than,
the most widely used clinical PDT agent, Photofrin, at
significantly reduced administered doses of photosensitizer
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Figure 7. Mice were imaged 24 hr, 48 hr or 1 week after photodynamic therapy (PDT). Images were acquired using the LabPet Small Animal
scanner, with a resolution of 135 mm full width at half -maximum peak height transaxial.14 The animal was anaesthetized under isoflurane
anaesthesia (1% at 2 l/min oxygen flow) and 37 MBq of 18F fluorodeoxyglucose (FDG) was administrated via the caudal vein in 200–300 ll of
physiological saline.
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suggests that this strategy could address one of the major
drawbacks of PDT, that of generalized photosensitivity.
The fact that no significant inhibition of tumour growth
was observed with conjugates of the same photosensitizers
with an irrelevant antibody confirms that the in vivo
effects for the relevant conjugates are attributable to anti-
body/antigen interactions.
The mechanism of action of the immunoconjugates,
demonstrated using anti-CD104-porphyrin 1 for consis-
tency throughout the investigations, points to a predomi-
nantly apoptotic mechanism in vitro, as shown by
annexin V/propidium iodide (Fig. 3) and caspase 3
(Fig. 5) assays, which are linked to depolarization of the
mitochondrial membrane (Fig. 4). Interestingly, these
results suggest an energy-dependent mechanism of cell
death, which may account for the much greater uptake of
FDG detected in vivo 24 hr post PDT (Fig. 7). Photo-
frin-mediated PDT, which operates by a predominantly
necrotic mechanism, following destruction of tumour vas-
culature, shows negligible increase in FDG uptake relative
to the control tumour. An alternative but not mutually
exclusive hypothesis is that the relevant conjugates induce
an important acute inflammatory response following
PDT. The energy consumed by the neutrophils involved
in this response could account for the increased FDG
uptake in the tumour volume and would tend to mask
any reduction in FDG uptake by the tumour cells, as a
result of cell death.
In summary, we have shown that two cationic porphy-
rin-based photosensitizers, bearing a single isothiocyanate
group, can be conjugated efficiently to three monoclonal
antibodies. Immunogenicity and photodynamic activity
are retained for all conjugates. The relevant antibody
conjugates induce cell death primarily by apoptosis when
activated with red light, and result in improved tumour
growth inhibition, relative to Photofrin, at significantly
lower administered photosensitizer doses. Relevant conju-
gates induce a large increase in uptake of FDG relative
to control tumours 24 hr post PDT, an effect not
observed for Photofrin; this suggests that the improved
tumour inhibition for the relevant conjugates may be
linked to differences in the mechanism of photodynamic
damage. Future studies with higher concentrations of
these immunoconjugates, coupled with an investigation
of any non-specific localization, are now needed to con-
firm the full potential of these derivatives and similar
compounds.
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